34results about "Platelet-derived growth factor" patented technology

The invention discloses a platelet growth factor derived polypeptide as well as a composition and application thereof. The amino acid sequence of the polypeptide is shown as Seq ID No: 1 (RP1601: LLKLLKKLLKKLLKK). KKIIKKL is used as a core active sequence, a variant library is designed by adopting a special design rule (AABB cycle rule), optimization is carried out by combining a polypeptide activity prediction system with a molecular docking technology, finally five candidate polypeptides are screened out, the polypeptide RP1601 has a better balance expression between drug effect and safety, and the polypeptide RP1601 is simple in structure, easy to synthesize and optimize and high in stability, and can be used for preparing a polypeptide RP1601. Therefore, the polypeptide is determined as an optimal candidate polypeptide; based on excellent anti-inflammatory, repair-promoting and anti-oxidation characteristics of the polypeptide, the invention further provides application of the polypeptide in cosmetics and medicines.

The present disclosure relates to a stable human platelet lysate composition; preferably a stable heparin-free human platelet lysate composition; methods for obtaining said composition and uses thereof.

The present invention relates to improved platelet-derived growth factor (PDGF) polypeptide variants, particularly polypeptides comprising the sequence of any one of SEQ ID NOs: 2 to 4 or a sequence having at least 80% similarity thereto, wherein the PDGF polypeptide exhibits increased stability, biological activity and / or solubility compared to the wild-type PDGF polypeptide of SEQ ID NO: 1. The present invention further provides nucleic acid sequences encoding the PDGF polypeptides of the present invention, and also provides a method for growing animal cells, comprising culturing the animal cells in a culture medium containing the PDGF polypeptide of the present invention.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

Methods for generating multipotent radial glia-like cells and astrocyte-like cells from human pluripotent stem cells are provided, along with related compositions.

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

This invention relates to a method for producing extracellular matrix using connective tissue cell culture and to the uses of the produced extracellular matrix. More specifically, it relates to a method for culturing connective tissue cells using a serum-free and heterogeneous culture medium, which can be effectively used to increase the amount of extracellular matrix produced. Furthermore, the extracellular matrix produced by the production method of this invention is derived from human cells and does not contain any heterogeneous components such as fetal bovine serum, making it safe and useful for future development of cell therapy agents, medical supplies, medical devices for tissue treatment, or cosmetic raw materials.

The present disclosure relates, in part, to a composition comprising a nucleic acid, wherein the nucleic acid encodes a protein which has a reduced abundance in a GTPase IMAP family 5 (GIMAP5) deficient subject or at least partially inhibits expression of a protein which has an increased abundance in a GIMAP5 deficient subject, as compared to a healthy subject. In certain embodiments, the composition is a nucleic acid-lipid particle. In certain embodiments, the composition is a polymer-based vehicle. In another aspect, the present disclosure relates to a recombinant viral vector comprising a nucleic acid encoding a protein which has a reduced abundance in a GIMAP5 deficient subject as compared to a healthy subject. In yet another aspect, the present disclosure provides a method of treating, ameliorating, and / or preventing liver disease and / or portal hypertension in a subject with administration of one or more compositions and / or vectors of the present disclosure.

The present invention provides a novel blood-derived growth-factor-containing composition. The present invention for solving the above problem is a method for preparing a growth-factor-containing composition from blood, the method comprising a step for separating platelet-rich plasma that does not contain a buffy coat component from the blood, and a step for adding citric acid and / or a salt thereof to the blood or a processed product thereof.

The invention discloses a preparation method of a platelet-derived growth factor BB. The preparation method comprises the following steps: cloning and implanting a coding gene of the platelet-derived growth factor BB into a prokaryotic expression vector to construct a recombinant prokaryotic expression vector, transferring the recombinant prokaryotic expression vector into a proper prokaryotic host cell, and culturing the prokaryotic host cell to obtain the platelet-derived growth factor BB recombinant prokaryotic expression vector. A non-soluble recombinant protein containing the platelet-derived growth factor BB is expressed, and a high-purity protein is separated. Compared with the existing reverse purification technology, the method for preparing the platelet-derived growth factor BB has the advantages that the purification steps are simple, the protein loss amount is reduced, the required purification consumables are low in price, and the cost can be greatly reduced in development and production.

The invention provides a growth factor-dextran conjugate as well as a preparation method and application thereof, the growth factor-dextran conjugate consists of a growth factor and dextran, and is obtained by coupling an amino group of the growth factor and a hydroxyl group of the dextran through a chemical reaction; the growth factor-dextran conjugate can protect the growth factor to enhance the stability of the growth factor, reduce the degradation of the growth factor in vivo and prolong the in vivo half-life period of the growth factor; coupled dextran can be combined with a cell surface receptor to promote cellular uptake of growth factors and enhance the effective action concentration of the growth factors in cells, has good biocompatibility and biological safety, and has wide application in research and development of drugs for wound repair and / or treatment of neurodegenerative diseases.

A process is provided for treating demineralized bone (DB) comprising incubating the DB with a solution of a chaotropic agent at a temperature in the range of about 12°C to about 30°C to increase the release of a bone growth factor followed by selectively removing the chaotropic agent while retaining the released growth factor and the DB. A product prepared by the process is also provided as is the use of said product to promote bone formation or bone fusion in a subject in need thereof.

The present invention relates to a method for producing bone marrow-derived endothelial precursor cells with enhanced angiogenic ability using PDGF-BB, and a method for producing a cell therapeutic agent for treating angiogenesis-related diseases using the same. Specifically, the present invention relates to a method for producing vascular endothelial precursor cells with enhanced angiogenic ability, which comprises the step of treating isolated vascular endothelial precursor cells with PDGF-BB and culturing them, a composition for promoting angiogenesis comprising vascular endothelial precursor cells and PDGF-BB as active ingredients, a method for producing a cell therapeutic agent for treating angiogenesis-related diseases, which comprises the step of mixing isolated vascular endothelial precursor cells, mesenchymal stem cells and PDGF-BB, and the cell therapeutic agent for treating angiogenesis-related diseases produced by the method.

The present invention is directed a fusion protein comprising IL-12 and GM-CSF, which are covalently attached. The fusion protein may further comprise a transmembrane domain C-terminal to IL-12 and GM-CSF. The present invention is also directed to mRNA-LNP delivery of the fusion protein. The present invention is also directed to a method for producing membranous IL-12 and GM-CSF, and transmembrane domain in cells. The method comprises the steps of transcribing mRNA from DNA sequence encoding the fusion protein with RNA polymerase, encapsulating the mRNA in lipid nanoparticles (LNPs), transfecting the mRNA-encapsulated LNPs into cells, and translating the mRNA in the cells to produce membrane bound IL-12 fused to GM-CSF cytokine protein to stimulate immune cells and tumor microenvironment.

Disclosed herein are compositions, methods, and systems for the purification and / or detection of recombinant and other proteins. In some embodiments, compositions may comprise recombinant protein with one or more sequences having substantial homology to RP-Tag Small or RP-Tag Large. In some cases, the disclosed compositions may be useful in binding or recognizing target proteins.

The described invention provides soft tissue grafts, hard tissue grafts, and composite soft / hard tissue grafts and methods of producing such grafts. The grafts comprise a three-dimensional carrier matrix, a growth factor composition comprising an autologous platelet-rich fibrin and a cell culture composition comprising a culture medium, a population of cells suspended in the culture medium, and cells impregnated on or in a surface of osteoconductive particles.

The invention relates to improved platelet-derived growth factor (PDGF) polypeptide variants, in particular polypeptides comprising a sequence of any one of SEQ ID NOs: 2-4 or a sequence with at least 80% similarity thereto, wherein the PDGF polypeptide exhibits increased stability, bioactivity and / or solubility compared to the wild-type PDGFB polypeptide of SEQ ID NO: 1. The invention further provides nucleic acid sequences encoding a PDGF polypeptide of the invention, and a method of growing an animal cell comprising cultivating the animal cell in a culture medium comprising a PDGF polypeptide of the invention is also provided.

The present invention relates to peptide ligands that bind to an extracellular or transmembrane region of PDGFR-alpha. The invention also relates to compositions comprising the peptide ligands and methods of using the same.

Described are aqueous and non-immunogenic injectable compositions derived from human umbilical cord and methods for their production. The non-immunogenic compositions are used for the treatment of joints in human subjects in need of joint treatment. The non-immunogenic compositions may comprise an aqueous human umbilical cord filtrate prepared without using exogenous enzymes that cause exogenous enzymatic degradation / digestion.

The present invention relates to a pharmaceutical composition containing stem cells in which vascular endothelial growth factor (VEGF) is overexpressed as an effective ingredient for preventing or treating neurodegenerative diseases. The stem cells in which VEGF is overexpressed according to the present invention effectively act against the neurodegenerative disease-induced VEGF reduction of neural stem cells in the SVC to inhibit the abnormal migration of neural stem cells, suppress inflammatory responses, and restrain the accumulation of cholesterol and spingolipids in the cerebral cortex, thus restoring the behavior exercise capacity of animal models, whereby the pharmaceutical composition can be used as an effective therapeutic agent for neurodegenerative diseases.

The invention provides a nano material for transforming chimeric antigen receptor CD34 + stem cells in vivo, a preparation method of the nano material and application of the nano material in products for treating aortic dissection, and belongs to the technical field of stem cell treatment. The preparation method of the nano material comprises the following steps: step a1, construction and transcription amplification of CAR-mRNA with VCAM-1scFv and VEGFA expression; and a2, carrying out liposome nanoparticle LNP encapsulation on the CAR-mRNA to obtain the LNP in which the CAR-mRNA is encapsulated, and carrying out targeted modification on the LNP in which the CAR-mRNA is encapsulated to obtain the CD34 antibody modified LNP in which the CAR-mRNA is encapsulated.

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

The present application is directed to PDGF-D prodomain or its mutant or fusion. The present application is also directed to a process or use of the PDGF-D prodomain or its mutant or fusion for inhibiting PDGFR phosphorylation, for inhibiting cell proliferation stimulated by PDGF, or for preventing and / or treating diseases associated therewith.

Provided herein is bioactive protein / peptide-modified PPCN (e.g., A5G81, QK, VEGF-C, etc.) and methods of ocular delivery and treatment of disease (e.g., glaucoma) therewith.

Disclosed herein are compounds of formula (I) wherein X, L1, and HSA conjugate are as defined herein, methods of preparation thereof, and methods of using thereof for improving cardiac repair, particularly post infarct.

The invention relates to improved platelet-derived growth factor (PDGF) polypeptide variants, in particular polypeptides comprising a sequence of any one of SEQ ID NOs: 2-4 or a sequence with at least 80% similarity thereto, wherein the PDGF polypeptide exhibits increased thermostability, bioactivity and / or solubility compared to the wild-type PDGFB polypeptide. The invention further provides nucleic acid sequences encoding a PDGF polypeptide of the invention, and a method of growing an animal cell comprising cultivating the animal cell in a culture medium comprising a PDGF polypeptide of the invention is also provided.

The present invention relates to the field of nanostructured protein materials, more specifically to therapeutic agents carrying fusion proteins which can be used for therapy.

Disclosed is an engineered exosome, comprising (a) an EGF polypeptide, fused to a first anchoring polypeptide, (b) a NGF polypeptide, fused to a second anchoring polypeptide, and (c) a PDGF-BB polypeptide, fused to a third anchoring polypeptide, wherein (a), (b) and (c) are anchored on a membrane of the exosome via the first, second and third anchoring polypeptide, respectively, and wherein the EGF polypeptide, the NGF polypeptide and the PDGF-BB polypeptide are exposed on an outer surface of the membrane of the exosome. Also disclosed are compositions, nucleic acid constructs, and uses of the exosome for wound healing.

The present application relates to methods for generating engineered human pluripotent stem cell-derived cardiac tissue, engineered cardiac tissue produced by such methods, and methods of their use.